Share Price:

APNASPENAspen Pharmacare Hldgs22979-195 (-0.84%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Regional Overviews

Aspen in Americas

Mexico and Brazil in the Latin America region continue to perform and lead in terms of revenue contribution and growth. The region actively promotes regional and global brands through hospital, prescription and over‑the-counter (“OTC“) sales. Brazil also has a manufacturing site which specialises in finished dose form (“FDF“).

Key Countries

Brazil
Canada
Chile
Colombia
Ecuador
Mexico
USA

Overview

Brand Therapeutic category

Diprivan

General anaesthetic

Meticorten

Corticosteroid

Milk of Magnesia

Antacids/antiflatulants

Perfalgen

Analgesic injectable

Xylocaine

Regional anaesthetic

5
Products
Launched

(2022: 20)

Product
Recalls

(2022: 1)

5 %
Average Staff
Turnover

(2022: 22)

Work-related
Facilities

(2022: Nil)

135
Sales
Representatives

(2022: 235)

250
Permanent
Employees

(June 2022: 714)

Revenue 2023
R’million
2022 (CER)
R’million
Change
%

Commercial Pharmaceuticals

Regional Brands

3 452

3 373

2

Sterile Focus Brands

1 627

1 657

(2)

Manufacturing

FDF - Other

19

-

>100

Total

5 098

5 030

1

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.

Contribution to Group revenue (%)
Revenue by segment (%)

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.